180 related articles for article (PubMed ID: 35895438)
21. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
[TBL] [Abstract][Full Text] [Related]
22. Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer.
Nakamura Y; Yokoyama S; Matsuda K; Tamura K; Mitani Y; Iwamoto H; Mizumoto Y; Murakami D; Kitahata Y; Yamaue H
Sci Rep; 2021 Jan; 11(1):441. PubMed ID: 33432066
[TBL] [Abstract][Full Text] [Related]
23. Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan.
Sato S; Nakamura Y; Oki E; Yoshino T
Clin Colorectal Cancer; 2023 Mar; 22(1):53-58. PubMed ID: 36567192
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer.
Fakih M; Sandhu J; Wang C; Kim J; Chen YJ; Lai L; Melstrom K; Kaiser A
JAMA Netw Open; 2022 Mar; 5(3):e221093. PubMed ID: 35258578
[TBL] [Abstract][Full Text] [Related]
25. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
26. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.
Bent A; Raghavan S; Dasari A; Kopetz S
Clin Colorectal Cancer; 2022 Jun; 21(2):89-95. PubMed ID: 35450837
[TBL] [Abstract][Full Text] [Related]
27. Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer.
Schøler LV; Reinert T; Ørntoft MW; Kassentoft CG; Árnadóttir SS; Vang S; Nordentoft I; Knudsen M; Lamy P; Andreasen D; Mortensen FV; Knudsen AR; Stribolt K; Sivesgaard K; Mouritzen P; Nielsen HJ; Laurberg S; Ørntoft TF; Andersen CL
Clin Cancer Res; 2017 Sep; 23(18):5437-5445. PubMed ID: 28600478
[No Abstract] [Full Text] [Related]
28. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
Haupts A; Roth W; Hartmann N
Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
[TBL] [Abstract][Full Text] [Related]
29. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer.
Symonds EL; Pedersen SK; Murray D; Byrne SE; Roy A; Karapetis C; Hollington P; Rabbitt P; Jones FS; LaPointe L; Segelov E; Young GP
Cancer; 2020 Apr; 126(7):1460-1469. PubMed ID: 31909823
[TBL] [Abstract][Full Text] [Related]
30. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
Parikh AR; Van Seventer EE; Siravegna G; Hartwig AV; Jaimovich A; He Y; Kanter K; Fish MG; Fosbenner KD; Miao B; Phillips S; Carmichael JH; Sharma N; Jarnagin J; Baiev I; Shah YS; Fetter IJ; Shahzade HA; Allen JN; Blaszkowsky LS; Clark JW; Dubois JS; Franses JW; Giantonio BJ; Goyal L; Klempner SJ; Nipp RD; Roeland EJ; Ryan DP; Weekes CD; Wo JY; Hong TS; Bordeianou L; Ferrone CR; Qadan M; Kunitake H; Berger D; Ricciardi R; Cusack JC; Raymond VM; Talasaz A; Boland GM; Corcoran RB
Clin Cancer Res; 2021 Oct; 27(20):5586-5594. PubMed ID: 33926918
[TBL] [Abstract][Full Text] [Related]
31. Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients.
Petrillo A; Salati M; Trapani D; Ghidini M
Curr Drug Targets; 2021; 22(9):1010-1020. PubMed ID: 33155906
[TBL] [Abstract][Full Text] [Related]
32. Ultrasensitive tumour-agnostic non-invasive detection of colorectal cancer recurrence using ctDNA methylation.
Xiao Y; Wang X; Weng H; Ding Z; Qian K; Jin W; Lu S; Ju L; He Z; Wang G; Xie X; Liu D; Fan Z; Wu K; Li S; Guo H; Qian G; Jiang W; Leng Y; Zhao J; Cao X; Peng M; Jiang C; Li L; Zhang Y; Wang X
Clin Transl Med; 2022 Sep; 12(9):e1015. PubMed ID: 36103400
[No Abstract] [Full Text] [Related]
33. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
[TBL] [Abstract][Full Text] [Related]
34. Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling.
Yaegashi M; Iwaya T; Sasaki N; Fujita M; Ju Z; Siwak D; Hachiya T; Sato K; Endo F; Kimura T; Otsuka K; Sugimoto R; Sugai T; Liotta L; Lu Y; Mills GB; Nakagawa H; Nishizuka SS
Br J Cancer; 2021 Apr; 124(9):1556-1565. PubMed ID: 33658639
[TBL] [Abstract][Full Text] [Related]
35. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
36. Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery.
Ng SB; Chua C; Ng M; Gan A; Poon PS; Teo M; Fu C; Leow WQ; Lim KH; Chung A; Koo SL; Choo SP; Ho D; Rozen S; Tan P; Wong M; Burkholder WF; Tan IB
Sci Rep; 2017 Jan; 7():40737. PubMed ID: 28102343
[TBL] [Abstract][Full Text] [Related]
37. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
[TBL] [Abstract][Full Text] [Related]
38. Circulating tumor DNA analysis detects micrometastatic disease and predicts recurrence in a patient with colon cancer: A case report.
Luo J; Zhou B; Zhao L; Yuan J; Zhou J; Shen L; Li F; Qian C
Medicine (Baltimore); 2023 Jul; 102(28):e34330. PubMed ID: 37443478
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
40. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
